Your browser is no longer supported. Please, upgrade your browser.
Settings
EBS [NYSE]
Emergent BioSolutions Inc.
Index- P/E9.01 EPS (ttm)7.15 Insider Own0.90% Shs Outstand53.30M Perf Week3.14%
Market Cap3.41B Forward P/E12.74 EPS next Y5.05 Insider Trans-16.76% Shs Float48.52M Perf Month7.23%
Income387.30M PEG0.98 EPS next Q1.54 Inst Own85.60% Short Float7.38% Perf Quarter3.96%
Sales1.71B P/S2.00 EPS this Y445.20% Inst Trans-0.18% Short Ratio5.09 Perf Half Y-39.89%
Book/sh28.57 P/B2.25 EPS next Y-37.48% ROA14.30% Target Price91.14 Perf Year-27.63%
Cash/sh10.34 P/C6.23 EPS next 5Y9.20% ROE28.60% 52W Range55.07 - 137.61 Perf YTD-28.14%
Dividend- P/FCF10.99 EPS past 5Y24.00% ROI14.30% 52W High-53.21% Beta0.94
Dividend %- Quick Ratio2.10 Sales past 5Y26.00% Gross Margin69.00% 52W Low16.93% ATR2.20
Employees2200 Current Ratio3.20 Sales Q/Q78.20% Oper. Margin31.70% RSI (14)55.84 Volatility3.77% 3.35%
OptionableYes Debt/Eq0.56 EPS Q/Q632.00% Profit Margin22.70% Rel Volume0.33 Prev Close63.65
ShortableYes LT Debt/Eq0.55 EarningsJul 29 AMC Payout0.00% Avg Volume703.26K Price64.39
Recom2.20 SMA203.63% SMA505.02% SMA200-23.27% Volume234,713 Change1.16%
May-05-21Downgrade Argus Buy → Hold
Apr-07-21Initiated The Benchmark Company Buy $150
Feb-24-21Upgrade Chardan Capital Markets Neutral → Buy $112
Feb-19-21Downgrade Chardan Capital Markets Buy → Neutral $112
Jan-08-21Downgrade Wells Fargo Overweight → Equal Weight $110
Sep-14-20Resumed JP Morgan Neutral $103
Jul-31-20Reiterated Chardan Capital Markets Buy $86 → $112
Sep-12-19Initiated Guggenheim Buy
Sep-04-19Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
Jul-25-21 04:21AM  
Jul-22-21 03:03PM  
Jul-20-21 07:25AM  
Jul-15-21 06:30AM  
Jul-07-21 09:39AM  
Jul-03-21 08:02AM  
Jul-02-21 04:11PM  
Jun-29-21 07:01AM  
Jun-24-21 09:19AM  
Jun-23-21 10:52AM  
09:06AM  
Jun-22-21 05:29AM  
Jun-21-21 05:01PM  
03:30PM  
02:00PM  
01:20PM  
12:34PM  
09:45AM  
09:10AM  
05:40AM  
01:00AM  
Jun-20-21 12:30PM  
11:35AM  
11:10AM  
10:42AM  
Jun-19-21 08:27AM  
Jun-18-21 08:20PM  
08:02PM  
07:15PM  
12:00PM  
10:55AM  
10:11AM  
10:00AM  
Jun-17-21 07:00PM  
06:40PM  
01:40PM  
11:20AM  
11:00AM  
11:00AM  
10:54AM  
10:05AM  
09:45AM  
09:06AM  
06:30AM  
06:12AM  
Jun-16-21 10:26PM  
10:26PM  
10:00PM  
06:47PM  
05:15PM  
04:29PM  
03:00PM  
02:00PM  
01:10PM  
12:39PM  
10:53AM  
10:45AM  
10:00AM  
05:23AM  
Jun-15-21 11:06PM  
06:26PM  
04:51PM  
04:01PM  
03:04PM  
02:25PM  
01:45PM  
12:44PM  
12:00PM  
10:52AM  
10:35AM  
10:00AM  
09:00AM  
05:40AM  
Jun-14-21 10:56PM  
09:00PM  
08:20PM  
06:52PM  
05:25PM  
02:51PM  
02:41PM  
01:20PM  
12:00PM  
11:05AM  
10:26AM  
10:00AM  
09:35AM  
08:30AM  
05:24AM  
Jun-13-21 01:18PM  
10:15AM  
Jun-12-21 04:55PM  
01:40PM  
12:06PM  
Jun-11-21 10:00PM  
05:25PM  
04:35PM  
02:27PM  
01:00PM  
12:10PM  
12:03PM  
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zoon Kathryn CDirectorMay 25Sale56.483,139177,29114,377May 27 04:37 PM
SULLIVAN LOUIS WDirectorMay 10Option Exercise18.6410,305192,08543,063May 11 04:18 PM
Bailey SueDirectorMar 04Sale92.378,168754,47824,427Mar 08 06:30 PM
Havey AdamEVP, Business OperationsMar 01Option Exercise40.9037,2791,524,81258,335Mar 03 06:07 PM
Havey AdamEVP, Business OperationsMar 01Sale99.3037,2793,701,64738,190Mar 03 06:07 PM
Kramer RobertPresident and CEOFeb 08Option Exercise30.7945,3971,397,961171,607Feb 09 05:23 PM
Kramer RobertPresident and CEOFeb 08Sale120.0345,3975,449,002139,210Feb 09 05:23 PM
Kramer RobertPresident and CEOJan 21Option Exercise26.4521,900579,255161,110Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 21Sale110.0321,9002,409,657139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Option Exercise26.452,23259,036141,442Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Sale110.002,232245,520139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 15Option Exercise25.6219,026487,446158,236Jan 19 04:28 PM
Kramer RobertPresident and CEOJan 15Sale106.0119,0262,016,901139,210Jan 19 04:28 PM
El-Hibri FuadChairmanNov 10Option Exercise26.4519,391512,8921,143,379Nov 12 06:30 PM
El-Hibri FuadChairmanNov 10Sale88.2119,3911,710,4801,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Option Exercise26.4520,000529,0001,143,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Sale95.2620,0001,905,2001,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 03Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 03Sale90.7420,0001,814,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Sale90.4420,0001,808,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanSep 24Sale98.8512,5351,239,0851,123,988Sep 25 07:00 PM
El-Hibri FuadChairmanSep 23Sale100.5813,0001,307,5401,136,523Sep 25 07:00 PM
El-Hibri FuadChairmanSep 17Sale100.6820,0002,013,6001,149,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 16Sale102.4820,0002,049,6001,169,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 10Sale102.6620,0002,053,2001,189,523Sep 11 09:21 PM
El-Hibri FuadChairmanSep 09Sale102.8020,0002,056,0001,209,523Sep 11 09:21 PM
SULLIVAN LOUIS WDirectorSep 02Option Exercise20.087,893158,49150,655Sep 04 08:08 PM
SULLIVAN LOUIS WDirectorSep 02Sale111.2228,4183,160,60642,762Sep 04 08:08 PM
Bailey SueDirectorAug 18Sale128.314,665598,56432,595Aug 19 05:08 PM
Harsanyi ZsoltDirectorAug 17Sale133.716,609883,66424,579Aug 18 09:12 AM
JOULWAN GEORGE ADirectorAug 11Sale124.116,000744,63526,771Aug 12 04:52 PM
Zoon Kathryn CDirectorAug 10Sale130.271,000130,27012,489Aug 11 04:43 PM
Richard RonaldDirectorAug 07Sale131.006,297824,9078,276Aug 11 04:46 PM